Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

DHDoris K. HansenLPLauren C. PeresDDDanai Dima

Discussion

Loading...

Member takes

Overview

Multicenter study finds early relapse in multiple myeloma post cilta-cel, suggesting risk-adapted therapy improves outcomes.

Key Points

  • The research aims to identify predictors of early relapse among patients receiving cilta-cel for relapsed/refractory multiple myeloma.
  • Conducted a multi-center study with 598 patients receiving cilta-cel at 15 U.S. centers.
  • Evaluated outcomes associated with high-risk features using logistic regression and Cox regression models.
  • Analyzed predictors of early relapse within 18 months and adjusted for baseline factors.
  • 33% had functional high-risk disease, which was linked to inferior progression-free survival (PFS).
  • Complete response rates were lower in patients with high-risk features compared to those without.
  • Independent risk factors for early relapse identified included functional high-risk disease and adapted IMS-IMWG high-risk definitions.

Cite This Study

Hansen et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d04ehttps://doi.org/10.1182/blood-2025-93
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Early Treatment Failure in Patients Receiving Ciltacabtagene‐Autoleucel for Relapsed/Refractory Multiple Myeloma2026
  2. 2Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality2025 · 7 citations
  3. 3Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma2025 · 4 citations
  4. 4CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.2023 · 117 citations
  5. 5Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma2025 · 5 citations